经济观察网 泰达生物（08189.HK）近期股价逆势走弱，业务进展与市场流动性受关注。 股票近期走势 2026年2月11日，泰达生物股价近7日累计下跌11.43%，同期AI医疗板块微涨0.94%，呈现逆势走弱态 势。当日成交额仅2.77万港元，换手率0.01%，市场流动性较低。技术面显示股价已跌破多条均线， MACD等指标动能疲软，短期市场信心不足。公司总市值约6.62亿港元，属于小盘股。 公司状况 2025年12月，泰达生物在"第十四届上市公司发展年会"上获"港股最具投资潜力上市公司"荣誉，反映市 场对其AI医疗技术布局的长期期待。但需注意，该事件距今已超两个月，近期股价表现与奖项预期形 成反差。 以上内容基于公开资料整理，不构成投资建议。 业务进展情况 公司AI医疗业务仍处于研发投入期，尚未形成规模收入。2025财年中报显示净亏损642.64万元，亏损同 比扩大55.86%，主营业务收入仍依赖生物复合肥料。2025年公司曾推进多项合作，如参与组建"云创AI 医疗联盟"、投建厦门AI诊疗项目等，但商业化成效需时间验证。未来需关注AI医疗场景的落地进度及 收入贡献。 行业政策与环境 AI医疗行业政策利好频出， ...

Core Viewpoint - The AI healthcare sector experienced a decline of 1.24% on February 13, with major stocks like Youke De leading the drop [1] Market Performance - The Shanghai Composite Index closed at 4082.07, down 1.26% [1] - The Shenzhen Component Index closed at 14100.19, down 1.28% [1] Capital Flow - The AI healthcare sector saw a net outflow of 2.719 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.799 billion yuan [1] - The sector experienced a net inflow of 920 million yuan from speculative funds [1]

Summary of Conference Call Notes Industry Focus - The focus is on the **AI healthcare sector**, particularly the integration of artificial intelligence in medical applications and services [1][2]. Core Insights and Arguments - The **Chinese government** emphasizes the need to promote large-scale commercial applications of AI, aiming to enhance the AI industry and expand high-value application scenarios [1]. - Recent advancements include **DeepSeek's version update** and the launch of **GLM-5**, indicating continuous breakthroughs in AI models [2]. - The **AI healthcare sector** is gaining traction due to supportive policies, technological advancements, and the gradual commercialization of pathology-assisted diagnostics [2]. - Clear application scenarios for AI in healthcare have been identified: - **B-end applications**: Involvement in medical imaging, surgical robots, in vitro diagnostics, and radiotherapy. - **C-end applications**: Empowering health management, chronic disease monitoring, personalized treatment suggestions, and academic research for doctors [2]. - Continuous policy support is evident through various documents that outline development directions and commercial pathways for AI in healthcare [2]. - The **first inclusion of "AI-assisted"** in the pricing project guidelines for pathology services marks a significant step towards commercialization [2]. - National-level AI application pilot platforms are being promoted in regions like **Beijing and Zhejiang**, enhancing industry conversion efficiency [2]. Additional Important Content - The **AI application market** is experiencing a surge in interest, driven by competition among major tech companies (ByteDance, Tencent, Alibaba, Baidu) in the general AI application field [3]. - Recent achievements, such as **ByteDance's Seedance 2.0**, demonstrate a shift from mere generation capabilities to commercial viability [3]. - The performance of companies like **Tempus** supports the feasibility of AI healthcare business models [3]. - Investment recommendations include companies such as **Dian Diagnostics, KingMed Diagnostics, and Meinian Health** [4]. - Risks highlighted include potential delays in policy implementation and slow commercialization of products or services [5].

2月12日，医渡科技(02158)发布最新股份回购公告：公司当日以每股约5.95港元的价格回购约56万股， 总耗资超330万港元，实现连续第14个交易日密集回购，累计回购金额已突破6400万港元，以连贯稳健 的资本动作，持续传递对自身价值与行业前景的双重信心。 业务端的突破进一步夯实回购底气：近日，医渡科技与华中科技大学同济医学院附属同济医院(下称"同 济医院")联合申报的胃肠肿瘤诊疗多模态AI数据库项目成功入选国家工信部2025年人工智能医疗器械创 新任务"揭榜挂帅"名单。作为国家为加速关键核心技术攻关、推动科技成果转化设立的重大创新机 制，"揭榜挂帅"名单的入选，既彰显了其在AI医疗领域的硬实力，也印证了其业务布局与国家战略需求 的高度契合，为公司在AI医疗商业化浪潮中抢占先机奠定基础。 2月11日，国务院以"深化拓展'人工智能+'、全方位赋能千行百业"为主题，举行第十八次专题学习。会 议指出，"人工智能+"前景广阔，将不断带动消费和产业升级，在各个领域打开新的增量空间。 这一高层定调为AI医疗行业注入强劲发展动力，医渡科技长期深耕的赛道契合"人工智能+医疗健康"的 核心赋能方向，其持续回购行为也成为对行 ...

2月11日，国务院以"深化拓展'人工智能+'、全方位赋能千行百业"为主题，举行第十八次专题学习。会 议指出，"人工智能+"前景广阔，将不断带动消费和产业升级，在各个领域打开新的增量空间。 这一高层定调为AI医疗行业注入强劲发展动力，医渡科技长期深耕的赛道契合"人工智能+医疗健康"的 核心赋能方向，其持续回购行为也成为对行业趋势的积极回应。 智通财经APP获悉，2月12日，医渡科技(02158)发布最新股份回购公告：公司当日以每股约5.95港元的 价格回购约56万股，总耗资超330万港元，实现连续第14个交易日密集回购，累计回购金额已突破6400 万港元，以连贯稳健的资本动作，持续传递对自身价值与行业前景的双重信心。 业务端的突破进一步夯实回购底气：近日，医渡科技与华中科技大学同济医学院附属同济医院(下称"同 济医院")联合申报的胃肠肿瘤诊疗多模态AI数据库项目成功入选国家工信部2025年人工智能医疗器械创 新任务"揭榜挂帅"名单。作为国家为加速关键核心技术攻关、推动科技成果转化设立的重大创新机 制，"揭榜挂帅"名单的入选，既彰显了其在AI医疗领域的硬实力，也印证了其业务布局与国家战略需求 的高度契合，为公司在 ...

Group 1 - The AI medical sector increased by 0.24% compared to the previous trading day, with Youke De leading the gains [1] - The Shanghai Composite Index closed at 4134.02, up 0.05%, while the Shenzhen Component Index closed at 14283.0, up 0.86% [1] - The net inflow of main funds in the AI medical sector was 863 million yuan, while retail funds experienced a net outflow of 47.14 million yuan [1] Group 2 - The table detailing the individual stock performance within the AI medical sector was referenced but not included in the summary [1] - The data was compiled by Securities Star using public information and generated by AI algorithms [1]

Core Viewpoint - The stock price of Eagle Eye Technology-B has shown a significant increase of 5.22% over the past week, indicating positive market sentiment and potential growth in the AI healthcare sector [1][2]. Price Performance - The stock price fluctuated with a range of 12.75%, closing at 12.30 HKD on February 12, 2026. Technical indicators such as the MACD histogram turned positive, and the KDJ J-line rebounded from the oversold area to 71.296, suggesting improved short-term momentum [1]. Institutional Insights - Analysts have set a target average price of 13.29 HKD for Eagle Eye Technology-B, indicating potential upside from the current price level. There is a market focus on the alignment of its AI healthcare business with policy directions [2]. Recent Events - The AI healthcare industry has gained attention from policymakers, with a special study held by the State Council on February 11, 2026, emphasizing the deepening application of "Artificial Intelligence+" across various sectors. Additionally, OpenAI launched the ChatGPTHealth feature in January 2026, validating the commercialization path for AI in healthcare and enhancing industry optimism [3].

早 报 精 选 1、李强：全面推进人工智能科技创新、产业发展和赋能应用，培育壮大新质生产力。 2、国务院：到2035年全面建成全国统一电力市场体系。 3、国务院国资委：央企要积极扩大算力有效投资。 4、DeepSeek更新，上下文达百万级token。 5、巨力索具公告，未签署过4.58亿的海南项目。 宏 观 新 闻 1、2月11日，国务院以深化拓展"人工智能+"、全方位赋能千行百业为主题，进行第十八次专题学习。国务院总理李强在主持学习时 强调，要深入学习贯彻习近平总书记关于人工智能发展的重要指示精神和党中央有关决策部署，全面推进人工智能科技创新、产业发 展和赋能应用，培育壮大新质生产力，推动高质量发展。 2、国务院办公厅日前印发《关于完善全国统一电力市场体系的实施意见》。《意见》指出，推动电力资源在全国范围内优化配置， 优化全国统一电力市场体系实现路径，完善跨省跨区电力交易制度。《意见》还提出，到2035年，全面建成全国统一电力市场体 系，市场功能进一步成熟完善，市场化交易电量占比稳中有升。 3、国务院国资委日前提出，中央企业要强化投资牵引，积极扩大算力有效投资，推进"算力+电力"协同发展，提升全链条数据治理 ...

Company Summary - Yidu Tech (02158) announced a share buyback on February 11, repurchasing over 480,000 shares at approximately HKD 6 per share, totaling nearly HKD 3 million, marking the thirteenth consecutive trading day of intensive buybacks, with a cumulative buyback amount exceeding HKD 61 million, demonstrating long-term confidence in the company's value [1][1][1] - Recently, Yidu Tech achieved a business milestone by successfully entering the national Ministry of Industry and Information Technology's "2025 Artificial Intelligence Medical Device Innovation Task" list with a multimodal AI database project for gastrointestinal tumor diagnosis in collaboration with Tongji Hospital of Huazhong University of Science and Technology [1][1][1] Industry Summary - The AI medical sector is at a critical juncture for commercialization, with CITIC Securities reporting that medical AI will accelerate the restructuring of the trillion-dollar pharmaceutical market [1][1][1] - CITIC Securities predicts a fundamental change in the logic of AI medical applications by 2026, driven by clearer and stronger payment capabilities from payers this year, suggesting that 2026 will likely see greater certainty in AI medical commercialization and open up new commercial opportunities [1][1][1] - Key areas to focus on include AI pharmaceuticals, grassroots AI medical applications, medical data circulation and trading, AI pathological diagnosis, AI medical models, and C-end expansion channels, along with related targets [1][1][1]

Company Summary - Medicure Technology (02158) announced a share buyback on February 11, repurchasing over 480,000 shares at approximately HKD 6 per share, totaling nearly HKD 3 million, marking the thirteenth consecutive trading day of intensive buybacks, with a cumulative buyback amount exceeding HKD 61 million, demonstrating long-term confidence in the company's value [1][1][1] - Recently, Medicure Technology achieved a business milestone by successfully entering the national Ministry of Industry and Information Technology's 2025 AI medical device innovation project list with a multimodal AI database project for gastrointestinal tumor diagnosis and treatment in collaboration with Tongji Hospital of Huazhong University of Science and Technology [1][1][1] Industry Summary - The AI medical sector is at a critical juncture for commercialization, with CITIC Securities reporting that medical AI will accelerate the restructuring of the trillion-dollar pharmaceutical market [1][1][1] - CITIC Securities predicts a fundamental change in the logic of AI medical applications by 2026, driven by clearer and stronger payment capabilities from payers this year, suggesting a stronger certainty for AI medical commercialization in 2026 [1][1][1] - Key areas for investment focus include AI drug development, grassroots AI medical applications, medical data circulation and trading, AI pathology diagnosis, AI medical models, and C-end expansion channels [1][1][1]